Chicago, IL (PRWEB) August 21, 2013
The prescription drug resource center DrugRisk.com is announcing updated information for patients taking the blood thinner Pradaxa. Recent court records show the number of patients who have filed a lawsuit alleging internal bleeding from the drug have risen sharply in the past month*.
DrugRisk provides patients taking popular prescription drugs with the latest warnings, recalls, studies and legal news to improve safety and awareness. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.
Pradaxa is a blood thinner approved by the FDA in 2010 as a stroke preventative for patients with atrial fibrillation. Experts disagree, however, about its risks for internal bleeding. The FDA has advised Pradaxa is no more dangerous than traditional blood thinner warfarin**.
Others, like the Institute for Safe Medication Practices, have warned that patients may be nearly 5 times as likely to die from Pradaxa bleeding than from bleeding with warfarin***. DrugRisk has also added a recent study from the Netherlands which suggests patients taking newer blood thinners like Pradaxa may be 55% more likely to suffer internal bleeding****.
Due to the number of patients who have filed a Pradaxa lawsuit alleging internal bleeding, cases have been consolidated to a special federal court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Now, DrugRisk has learned the latest court records from the Judicial Panel on Multidistrict Litigation show the number of cases filed has increased from 1133 on July 10th to 1389 on August 15, a rise of over 22%*.
Anyone affected by internal bleeding after taking Pradaxa is encouraged to visit DrugRisk.com or speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.
Visit http://www.DrugRisk.com today for more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer.
*Judicial Panel on Multidistrict Litigation, 8/15/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL-Dockets_By_District-August-15-2013.pdf
**FDA, 11/2/12; http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
***Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
****Gastroenterology, July 2013; gastrojournal.org/article/S0016-5085(13)00290-4/fulltext